Similar articles

• Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns.

  Leuridan E, Van Damme P. Leuridan E, et al. Vaccine. 2007 Aug 21;25(34):6296-304. doi: 10.1016/j.vaccine.2007.06.020. Epub 2007 Jun 29. Vaccine. 2007. PMID: 17629601 Review.
• Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia.

  Wood JG, Gidding HF, Heywood A, Macartney K, McIntyre PB, Macintyre CR. Wood JG, et al. Vaccine. 2009 Jan 7;27(2):313-8. doi: 10.1016/j.vaccine.2008.09.095. Epub 2008 Oct 31. Vaccine. 2009. PMID: 18977272
• Loss of maternally-acquired measles antibody during infancy in Ilorin, Nigeria.

  Babaniyi OA, Parakoyi DB, Aiyedun BA, Bello MA. Babaniyi OA, et al. J Trop Pediatr. 1995 Apr;41(2):115-7. doi: 10.1093/tropej/41.2.115. J Trop Pediatr. 1995. PMID: 7776394
• Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants.

  Gatchalian S, Yao Y, Zhou B, Zhang L, Yoksan S, Kelly K, Neuzil KM, Yaïch M, Jacobson J. Gatchalian S, et al. Vaccine. 2008 Apr 24;26(18):2234-41. doi: 10.1016/j.vaccine.2008.02.042. Epub 2008 Mar 18. Vaccine. 2008. PMID: 18394765 Clinical Trial.
• The potential use of DNA vaccines for neonatal immunization.

  Reddy ST, Ertl HC. Reddy ST, et al. Curr Opin Mol Ther. 1999 Feb;1(1):22-9. Curr Opin Mol Ther. 1999. PMID: 11249679 Review. No abstract available.